A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy
Active, not recruiting · Phase 2, Phase 3 · NCT05707377
Conditions: Primary Membranous Nephropathy
At a glance
- Research payments reported, 2025
- $1.7M
- U.S. investigators named
- 11
- Sites paid
- 15
- Planned or actual enrollment
- 178
About the trial
- Sponsor
- BeOne Medicines
- Tested
- Zanubrutinib (drug), Tacrolimus (drug)
- Dates
- Started 2023-04-17; completion 2027-10
- Results posted
- Not yet
The primary objectives of this study are: In Part 1 to evaluate the efficacy of zanubrutinib as measured by proteinuria reduction, and in Part 2 to evaluate the efficacy of zanubrutinib compared with tacrolimus as measured by complete remission rate, in participants with primary membranous nephropathy (PMN) who are on optimal supportive care.
From ClinicalTrials.gov, last updated 2026-09-11. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beigene, Ltd. reported $1.7M in research payments for this study in 2025 (96 payments).
Products named: Brukinsa
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Vinod M. Assomull SR., MD Nephrology (Kidney) · Granada Hills, CA
- Dayan K. Gandhi, M.D, M.S Nephrology (Kidney) · Northridge, CA
- Richard A. Lafayette, M.D. Nephrology (Kidney) · Stanford, CA
- Yonatan Peleg Nephrology (Kidney) · Chicago, IL
- Stuart M. Sprague, DO Nephrology (Kidney) · Evanston, IL
- Jonathan P. Tolins, M.D. Nephrology (Kidney) · Edina, MN
- Manish Anand, MD Nephrology (Kidney) · Vineland, NJ
- Mark Vishnepolsky, M.D. Nephrology (Kidney) · Las Vegas, NV
- Barry R. Gorlitsky, MD Nephrology (Kidney) · Greenville, SC
- Sreedhar A. Mandayam, M.D. Nephrology (Kidney) · Houston, TX
- Ashraf El-meanawy, MD, PH.D, MS Nephrology (Kidney) · Milwaukee, WI
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- The Board of Trustees of the Leland Stanford Junior University $448,092
- Intermed Consultants,ltd. $383,253
- Amicis Research Center $246,294
- Kidney Specialist of Southern Nevada $245,232
- University of Cincinnati Cancer Center $112,471
- Carolina Nephrology $90,217
- Northwestern university $56,592
- The Medical College of Wisconsin, Inc. $47,926
- Kidney Specialists of Southern Nevada (ksosn) $45,288
- Prolato Clinical Research Center $21,046
- Northwestern University $12,865
- Prolato Research LLC $5,960
- Northshore University Healthsystem - Evanston Hospital, IL $4,250
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.